Attention: This platform is in beta mode. Expect some changes and adjustments.

AI Market Mood: Stock Dashboard

NKTX


Fundamental

Company: Nkarta Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -1.39
Insider Own: 20.39%
Shs Outstand: 71.02M
Perf Week: -8.98%
Market Cap: 126.71M
Forward P/E: -
EPS next Y: -1.23
Insider Trans: -0.01%
Shs Float: 56.55M
Perf Month: -25.36%
Enterprise Value: -78.99M
PEG: -
EPS next Q: -0.31
Inst Own: 71.43%
Short Float: 16.00%
Perf Quarter: -23.10%
Income: -102.61M
P/S: -
EPS this Y: 17.80%
Inst Trans: -1.95%
Short Ratio: 10.49
Perf Half Y: 4.94%
Sales: 0.00M
P/B: 0.37
EPS next Y Percentage: 6.44%
ROA: -21.39%
Short Interest: 9.05M
Perf YTD: -28.35%
Book/sh: 4.76
P/C: 0.45
EPS next 5Y: 6.82%
ROE: -26.69%
52W High: 3.16 -43.46%
Perf Year: -29.49%
Cash/sh: 3.97
P/FCF: -
EPS past 3/5Y: 15.10% -19.86%
ROIC: -25.14%
52W Low: 1.31 36.18%
Perf 3Y: -84.20%
Dividend Est.: -
EV/EBITDA: -
Sales past 3/5Y: - -
Gross Margin: -
Volatility W: 5.08%
Volatility M: 6.00%
Perf 5Y: -94.39%
Dividend TTM: -
EV/Sales: -
EPS Y/Y TTM: 25.84%
Oper. Margin: -
ATR (14): 0.12
Perf 10Y: -
Dividend Ex-Date: -
Quick Ratio: 15.23
Sales Y/Y TTM: -
Profit Margin: -
RSI (14): 33.95
Recom: 1.29
Dividend Gr. 3/5Y: - -
Current Ratio: 15.23
EPS Q/Q: 23.85%
SMA20: -12.15%
Beta: 0.84
Target Price: 11.80
Payout: -
Debt/Eq: 0.23
Sales Q/Q: -
SMA50: -15.23%
Rel Volume: 0.65
Prev Close: 1.81
Employees: 157
LT Debt/Eq: 0.21
Earnings: Nov 10 AMC
SMA200: -9.11%
Avg Volume: 863.06K
Price: 1.78
IPO: Jul 10, 2020
Option/Short: Yes / Yes
EPS/Sales Surpr.: 4.89% -
Trades:
Volume: 273,153
Change: -1.44%

Technical:


Latest News:

Cullinan stock rises on Amgen's Blincyto data (NASDAQ:CGEM) | Seeking Alpha very bullish
CGEM AMGN ADCT ALLO AZN AUTL BMY IPSC GILD MOR NKTX NVS

Summary: Cullinan Therapeutics (CGEM) stock surged ~58% last week after positive data for CD19-targeting therapy similar to competitor Amgen's Blincyto, showing efficacy against autoimmune diseases like rheumatoid arthritis and systemic sclerosis.

Full article
2024-04-27T19:44:12Z